CCM
PYXS icon

CAAS Capital Management’s Pyxis Oncology PYXS Stock Holding History

CAAS Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-50,000
Closed -$549K – 880
2021
Q4 		$549K Buy
+50,000
New +$572K 0.01% 529

Other funds holding PYXS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

CAAS Capital Management's PYXS Position: Q1 2022 in Review

CAAS Capital Management sold out of Pyxis Oncology (PYXS) in Q1 2022, closing a stake of 50,000 shares — an estimated $549K sold.

CAAS Capital Management first reported a position in PYXS in Q4 2021 and held it in 1 quarter. The position peaked at $549K in Q4 2021. 45 funds tracked by Wall St. Rank hold PYXS as of Q1 2022.

  • CAAS Capital Management reported no remaining Pyxis Oncology position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 50,000 Pyxis Oncology shares in Q1 2022, an estimated $549K.
  • CAAS Capital Management first reported a position in Pyxis Oncology in Q4 2021 and held it in 1 quarter.
  • CAAS Capital Management's Pyxis Oncology position peaked at $549K in Q4 2021.
  • 45 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.